Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Crisugabalin on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Crisugabalin is a twice-a-day capsule for long-lasting nerve pain. It was discovered and developed in China by Haisco Pharmaceutical Group, where it is sold as 思美宁® and was known in trials by the code HSK16149.
China's National Medical Products Administration (NMPA) approved it in May 2024, and the current Chinese label covers adults with:
It is a prescription neurology medicine and should be started and reviewed by a neurologist, pain specialist, diabetologist or dermatologist.
Crisugabalin is built on the shape of GABA, one of the brain's natural calming messengers, but it does not act on GABA receptors themselves. Instead, it attaches to a part of the calcium channels on over-active pain nerves known as the alpha-2-delta subunit. The label is honest that its exact mechanism is not fully understood. In practice, it quietens the faulty pain signals that damaged nerves keep sending.
Diabetic nerve pain: a phase 2/3 trial in China, published in JAMA Network Open in 2024, treated patients for 13 weeks. Average daily pain scores (0 to 10) fell by 2.24 points on 20 mg twice daily and 2.16 points on 40 mg twice daily, against 1.23 points on placebo. More than half of patients on the lower dose (57.3%) had their pain cut by at least 30%, compared with 31.6% on placebo.
Post-shingles nerve pain: a phase 3 trial of 366 adults, published in JAMA Dermatology in 2024, ran for 12 weeks. Pain scores fell by about 2.3 points on 20 mg twice daily and 2.5 points on 40 mg twice daily, against about 1.0 point on placebo. At least a 30% drop in pain was seen in 61.2% and 54.5% of patients on the two doses, compared with 35.5% on placebo.
According to the Chinese label, it can be taken with or without food:
Side effects rise with dose, so your doctor will use the lowest dose that controls the pain.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Dizziness and sleepiness: these are the main side effects. Across the two controlled trials, dizziness affected 22.7% of people on crisugabalin against 5.7% on placebo, and sleepiness 7.5% against 0.3%. About 8 in 10 of these episodes began in the first week, and almost all were mild to moderate. Do not drive or use machines until you know how it affects you.
Stopping because of side effects: 5.1% of patients in the diabetic nerve pain trial (placebo 1.1%) and 2.0% in the post-shingles trial (placebo 0%). It is not recommended in pregnancy or breastfeeding, and safety in under-18s has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For another pain medicine that we import on prescription, see our page on Journavx.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The 20 mg capsules are stored sealed at no more than 25°C and travel in their original blister packs under temperature-controlled shipping. At 20 mg twice a day, one month of treatment is about 60 capsules, so we plan quantities around your prescribed dose. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid specialist's prescription.
Diabetes and pain clinics in the capital see many people with burning foot pain, and our New Delhi dispatch point means short delivery times.
Capsules can be sent to the patient's home or the treating clinic once the prescription and papers are checked.
Pain specialists and diabetologists in Bangalore can request the medicine for a named patient, with a quote shared before ordering.
With a large diabetes population, Chennai patients with long-standing nerve pain can use the same documented import route.
We plan monthly or longer supplies so treatment is not interrupted between refills.
Deliveries to Kolkata and the eastern states travel in sealed original packs with tracking at each step.
Patients with nerve pain after shingles can have their supply arranged on a dermatologist's or neurologist's prescription.
The treating doctor can send us the prescription and kidney test report to start the import.
Patients under specialist care in Vellore can receive the medicine at home or at the hospital pharmacy.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to their address or clinic.
We coordinate delivery to patients and clinics across Uttar Pradesh.
Patients across Kerala can receive their capsules in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
